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Abstract: Ischaemic reperfusion (IR) injury is a major cause of graft loss, morbidity and mortality following orthotopic
liver transplantation (OLT). Demand for liver transplantation has resulted in increasing use of marginal grafts that are
more prone to IR injury. Remote ischaemic preconditioning (RIPC) reduces IR injury in experimental models, but
recipient RIPC has not been evaluated clinically.
Methods: A single-centre double-blind randomized controlled trial (RCT) is planned to test the hypothesis that
recipient RIPC will reduce IR injury. RIPC will be performed following recipient anaesthetic induction but prior to
skin incision. The protocol involves 3 cycles of 5 min of lower limb occlusion with a pneumatic tourniquet inflated to
200 mmHg alternating with 5 min of reperfusion. In the control group, the sham will involve the cuff being placed on
the thigh but without being inflated.
The primary endpoint is ability to recruit patients to the trial and safety of RIPC. The key secondary endpoint is a
reduction in serum aspartate transferase levels on the third post-operative day.
Discussion: RIPC is a promising strategy to reduce IR injury in liver transplant recipients as there is a clear experimental
basis, and the intervention is both inexpensive and easy to perform. This is the first trial to investigate RIPC in liver
transplant recipients.
Trial registration: Clinicaltrials.gov NCT00796588
Keywords: Liver transplantation, Remote ischaemic preconditioning, Ischaemia reperfusion injury, Outcome, Aspartate
transferase
Ischaemia reperfusion (IR) injury, the injury which oc-
curs when an organ’s blood supply is interrupted and
reconstituted, is a major cause of morbidity and mortal-
ity post liver transplantation and is believed to account
for at least 10 % of early graft loss [1]. Grafts from ex-
tended criteria donors are more prone to IR injury and
the use of grafts from donors after cardiac death (DCD)
is associated with a two-fold increase in risk of death
and graft loss post transplantation in UK centres [2].
Due to a recent widening of the criteria for liver trans-
plantation, there is greater demand for an already scare
resource. In the UK, the use of grafts from DCD donors
has increased from 6.9 % in 2005 [2] to 19.1 % of grafts
implanted in 2013 [3]. There is no current accepted
treatment of IR injury and as such strategies to amelior-
ate IR injury are of key clinical importance.
Ischaemic preconditioning (IPC), first described in
1986 in a canine cardiac model [4] has been shown to
ameliorate warm hepatic IR injury in small animal
models. Several small trials have been performed investi-
gating the role of IPC of donor livers prior to retrieval
[5–8]. The results are conflicting with only one trial
demonstrating a better clinical outcome with fewer clin-
ical episodes of clinical rejection in grafts from extended
criteria donors following IPC [7], and two trials demon-
strating a reduction in serum transaminases post trans-
plantation [7, 8] with one trial reporting higher
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transaminase levels post transplantation following IPC
[5]. No trial was able to demonstrate a reduction in graft
loss or post-operative morbidity and mortality; however,
none of the trials were powered to demonstrate a reduc-
tion in morbidity or mortality.
Paradoxically in small animal models, IPC has been
shown to place added stress on the recovering liver
impairing liver regeneration [9, 10], and in a multi-
variate analysis of patients undergoing hepatic resection,
IPC was found to be an independent risk factor for post-
operative morbidity [11].
Remote ischaemic preconditioning (RIPC), first de-
scribed in 1993 again in a canine cardiac model [12] has
been found to provide protection against IR injury with-
out adding stress to the target organ and as such is an
attractive prospect for reducing IR injury in liver trans-
plant recipients. Although RIPC has been shown to
ameliorate hepatic IR injury in small animal models [13,
14], there has been no human liver transplant trial.
Three recent trials have been performed in kidney trans-
plantation including both living [15, 16] and deceased
donors [17]. Two trials demonstrated evidence of an im-
provement in early graft function [15, 17]; however, one
trial failed to demonstrate any evidence of improved
graft function or reduced levels of biomarkers of graft
injury [16]. Our aim is to perform a double-blinded ran-
domized control trial to investigate the protection
gained by RIPC in liver transplant recipients.
Methods/design
Study design and setting
RIPCOLT has been designed as a prospective double-
blind randomized control trial with both surgeon and
patient blinded to whether the recipient has received
preconditioning. This protocol has been designed ac-
cording to the SPIRIT guidelines [18]. The pilot will be
carried out in a single centre—the Royal Free Hospital,
London, with a subsequent multi-centre trial to establish
cost effectiveness.
Ethical approval
This trial has been approved by both the ethical board
of the National Research Ethical Service (11/H0720/4)
and the Royal Free Hospital/University College London
ethical board (8191).
The trial has been registered with clinicaltrials.gov
(NCT00796588).
Participants
The pilot study will include 50 patients undergoing
elective deceased donor liver transplantation at the Royal
Free Hospital, London. Data will then be analysed re-
garding trial recruitment, completion of RIPC protocol,
safety and preliminary evidence of efficacy to allow the
endpoints and power of a subsequent multi-centre RCT
to be designed. All patients undergoing deceased donor
liver transplantation at the Royal Free Hospital will be
considered for inclusion in the trial; exclusion criteria
are contained in Table 1.
Recruitment
Patients will be identified upon admission for transplant
assessment and will be screened for inclusion and exclu-
sion criteria. They will be provided with a patient infor-
mation sheet and allowed 24 h to review the information
prior to consenting by a member of the research team.
A copy of the consent form and patient information
sheet is included as an Additional file 1.
Power calculation
A power calculation is not required for a pilot feasibility
study [19]. However, guidance would suggest that 50 pa-
tients would be suitable for a feasibility study [20] with
25 randomized to receive RIPC and 25 to liver trans-
plantation as per standard.
Randomization
Participants are randomized to either the control or
intervention group following induction of anaesthesia
and collection of baseline blood samples. Randomization
is performed via a random number sealed envelope sys-
tem. Both the surgeon and the patient will be blinded to
whether the patient receives RIPC.
Trial protocol
Induction and maintenance of anaesthesia will be per-
formed by intravenous propofol. The use of volatile in-
haled induction agents such as sevoflurane have been
shown to exert a degree of pharmacological precondi-
tioning [21, 22] and as such they will be avoided.
Following induction but before the intervention, base-
line blood and urine samples will be collected for meas-
urement of pre-operative circulating cytokine levels and
Table 1 Exclusion criteria for trial
Exclusion criteria Re-transplantation
Patients under 16 years of age
Super-urgent transplantation
Lack of informed consent
Combined liver and kidney transplantation
Peripheral vascular disease
Varicose veins
Localized limb infection
Prior history of thrombo-embolic disease
Inclusion in another interventional trial
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markers of renal parenchymal injury in both the blood
and the urine.
A layer of stockinette will be applied to the left upper
thigh with a wide pneumatic tourniquet applied over it
in accordance with safe and recommended practices by
the Association of Peri-operative Registered Nurses
(AORN) [23] and Royal Free Hospital (RFH) departmen-
tal guidelines.
In those undergoing RIPC, the tourniquet will be in-
flated to 200 mmHg for 5 min followed by 5 min of re-
perfusion. This will be repeated three times.
In the control group, a sham will consist of the pneu-
matic tourniquet being placed on the left upper thigh
without being inflated. The transplant will then proceed
as standard.
Further blood samples will be collected 2 h following
reperfusion of the graft to measure circulating cytokine
levels post reperfusion. At the same time, two post re-
perfusion biopsies will be obtained. One of these biop-
sies will be fixed in 10 % natural buffered formalin for
48 h before being embedded in paraffin for H&E stain-
ing. IR injury will be graded by a pathologist according
to the Suzuki classification of liver IR injury [24]. The
second biopsy will be processed to extract fresh intra-
hepatic lymphocytes for analysis by flow cytometry.
A further blood and urine sample will be obtained
24 h post reperfusion to measure circulating cytokine
levels and markers of renal parenchymal injury both in
the blood and urine.
All patients will receive standard post-operative care.
Routine clinical data will be collected including local
complications as a result of RIPC, liver biochemistry,
clotting profiles, urea and creatinine levels, post-
operative complications, requirements for organ sup-
port, length of stay in the intensive care department and
total hospital stay. Patients will be followed up for
3 months. A flow diagram of the trial is included in
Fig. 1.
Outcome measures
The aim of this study is to assess the feasibility of
recruiting liver transplant recipients and performing
RIPC immediately prior to liver transplantations. The
primary and secondary outcomes (Table 2) will help de-
sign a subsequent multi-centre RCT of RIPC in liver
transplant recipients.
The criteria to progress to a full trial will be deter-
mined based on a consent rate of at least 60 % and post
randomization dropout rate from the study of less than
30 %.
The safety of RIPC will be measured by incidence
of localized complications following RIPC to include
the development of a deep vein thrombosis or pul-
monary embolus, the development of localized
cellulitis and pain or paresthesia of the left lower
limb following RIPC.
Data analysis
Data will be stored on password-protected UCL com-
puters in locked departments and will be anonymised
Fig. 1 Trial flow chart
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prior to use. Since this is a feasibility study, all analyses
other than recruitment rate and dropout rates should be
considered exploratory. RIPC and control groups will be
compared including both baseline characteristics and
secondary outcomes. Continuous variables will be pre-
sented using means and standard deviations or medians
and inter-quartile ranges, as appropriate, and binary var-
iables will be presented as frequency counts and per-
centages. The mean difference in proportions (for binary
outcomes) and the mean or median difference (for con-
tinuous outcomes) between the two groups will be ex-
plored and presented with 95 % confidence intervals.
This important data will be used to help the design of
the multi-centre RCT.
Results will be analysed via Statistical Package for So-
cial Sciences (SPSS) (IBM Chicago, IL, USA).
Dissemination
It is anticipated that the results of the study will be pre-
sented at the British Transplant Society annual meeting
and reported in a peer-reviewed journal of interest to
the transplant community.
We will publish a research report on the University
College London’s website and the Royal Free NHS trusts’
website.
Discussion
IR injury is a major cause of graft loss, morbidity and
mortality following liver transplantation [1, 25]. Due to
the increase utilization of grafts from extended criteria
donors which are more prone to IR injury [2], strategies
to ameliorate IR injury are a key research goal. We have
previously shown that RIPC reduces hepatic IR injury in
small animal models [13, 14, 26]. Previous trials have in-
vestigated IPC of donor livers prior to retrieval [5–8]
but failed to discern any clinical benefit. IR injury is not
confined to the liver but results in a systemic cytokine
storm, immune activation and multi-organ dysfunction.
In successful small animal models, preconditioning is
performed in the same individual as the reperfusion in-
jury occurs and therefore the process of performing
RIPC in the recipient may be more efficacious at redu-
cing the systemic inflammatory response associated with
IR injury reducing graft injury and end organ damage.
Several different protocols for RIPC exist, and there is
no current consensus as to which protocol is best. Three
cycles of 5 min of ischaemia have been shown to ameli-
orate IR injury in small animal models [27] and in pa-
tients undergoing coronary artery bypass graft surgery
[28], and as such we have elected to use this precondi-
tioning protocol in this trial.
This is the first trial to investigate whether recipient
RIPC can improve the outcome of human liver trans-
plant recipients. As such, we have chosen to perform a
pilot feasibility study of 50 patients initially. We have de-
signed this pilot study as a blinded randomized control
trial to give us the strongest pilot data to adequately
power and design the main trial. The data from this ini-
tial patient cohort will allow us to determine patient re-
cruitment, support of the liver transplant physicians and
surgeons, the feasibility of carrying out the period of
preconditioning between anaesthesia and commencing
surgery, the safety of limb ischaemia in liver transplant
recipients and to gain preliminary data on efficacy with
which to determine the endpoints and power required
for a subsequent multi-centre RCT.
We have chosen to exclude patients with a history of
venous thrombo-embolic disease, peripheral arterial dis-
ease and localized limb infections to minimize risk to
participating patients during a yet unproven interven-
tion. We have also chosen to exclude patients undergo-
ing liver transplantation for acute liver failure, on the
super-urgent list, as a transplantation in this setting is
associated with a threefold increased risk of morbidity
and mortality [29]. In a small trial, this would introduce
significant bias to the results. Furthermore, these pa-
tients have altered levels of consciousness due to
encephalopathy and consent is a problem for their inclu-
sion in this feasibility study. Patients undergoing simul-
taneous liver kidney transplantation have been excluded
to remove the bias of the added surgical stress and the
inclusion of patients with severe pre-operative renal im-
pairment who are offered combined transplants.
We have chosen AST on the third post-operative day
as an important endpoint as recent work has shown that
this correlates strongly with overall graft function, post-
Table 2 Primary and secondary endpoints
Primary endpoints Ability to recruit patients to the trial
Feasibility of performing RIPC in liver transplant
recipients
Safety of RIPC in liver transplant recipients
Secondary endpoints AST levels on the third post-operative day [30]
Incidence of acute kidney injury and need for
renal replacement therapy
Length of stay in intensive care and total
hospital stay
Incidence of vascular thrombotic events
Incidence of biliary complications
Incidence of post-operative infections
Incidence of acute rejection in the first months
post transplantation
Circulating cytokine levels 2 h post reperfusion
of the liver graft
T cell accumulation and activation in the liver
2 h post reperfusion
Urinary and serum NGAL levels 2 h post reperfusion
Robertson et al. Transplantation Research  (2016) 5:4 Page 4 of 6
operative mortality, need for organ support and inci-
dence of post-operative infective complications [30].
With current 90-day graft loss rates of 3.5 % and 90-day
mortality rates of 6.9 % following elective liver transplant
in the UK [29], a very large RCT would be required to
determine significant benefit following RIPC based on
these endpoints which is currently unfeasible. We have
also chosen to measure urinary and serum neutrophil
gelatinase-associated lipocalin (NGAL) levels as a sensi-
tive marker [31] of evidence of acute kidney injury (AKI)
post transplantation as this is a common complication
post liver transplantation, and reduction in the incidence
of end organ damage would provide a further hard end-
point to be used as an outcome in the future RCT in
combination with day 3 AST levels.
Evidence of a reduction in IR injury and the associated
systemic inflammatory response will be measured by
analysing the extent of IR injury and immune cell activa-
tion in post reperfusion biopsies and circulating serum
cytokines.
In summary, this is the first trial to investigate RIPC in
the setting of liver transplantation. RIPC has been shown
to ameliorate IR injury in renal transplantation [15, 17].
Samples from this trial will be analysed to provide evi-
dence of a reduction in immune activation by RIPC.
If successful, this inexpensive holistic intervention
could improve outcome following liver transplantation
and allow the implantation of more grafts from extended
criteria donors—widening the donor pool.
Additional file
Additional file 1: Patient Information Sheet & Consent Form. (DOC 43 kb)
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